1 enrolling by invitation. .
Follow Qian Jiang: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase Olverembatinib 20mg - Chronic Myeloid Leukemia | Enrolling by invitation | Qian Jiang | 100 | 2025-12-16 | 2026-02-03 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)
olverembatinib (1)
China (1)